Literature DB >> 8497058

Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.

S Chada1, C E DeJesus, K Townsend, W T Lee, L Laube, D J Jolly, S M Chang, J F Warner.   

Abstract

To evaluate the ability of murine anti-human immunodeficiency virus type 1 (HIV-1) IIIB env cytotoxic T lymphocytes (CTL) to recognize and lyse HIV-1-infected cells, we have constructed a human cell line (Hu/Dd) expressing both the CD4 receptor and the murine H-2Dd major histocompatibility complex (MHC) class I protein. This cell line can be productively infected with HIV-1 and can also function as a target for murine CD8+, class I MHC-restricted CTL directed against the envelope glycoprotein of HIV-1 IIIB. The ability of BALB/c anti-HIV-1 IIIB env CTL to specifically recognize and lyse Hu/Dd target cells infected with divergent HIV-1 strains was tested by using both prototypic and clinical HIV-1 strains. CTL generated by immunization of mice with syngeneic cells expressing either the native or V3 loop-deleted (delta V3) envelope glycoprotein from HIV-1 IIIB were able to recognize and specifically lyse Hu/Dd target cells infected with the HIV-1 prototypic isolates IIIB, MN, WMJ II, SF2, and CC as well as several HIV-1 clinical isolates. These results demonstrate that CTL determinants for HIV-1 env exist outside the hypervariable V3 region, anti-HIV-1 IIIB env CTL appear to recognize common determinants on diverse HIV-1 strains, and classification of HIV-1 strains based on neutralizing antibody reactivities does not appear to correspond to CTL recognition and lysis. The results suggest that the cell-mediated components of the immune system may have a broader recognition of divergent HIV-1 strains than do the humoral components.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497058      PMCID: PMC237685          DOI: 10.1128/JVI.67.6.3409-3417.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  HIV revealed: toward a natural history of the infection.

Authors:  D Baltimore; M B Feinberg
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160.

Authors:  H Takahashi; S Merli; S D Putney; R Houghten; B Moss; R N Germain; J A Berzofsky
Journal:  Science       Date:  1989-10-06       Impact factor: 47.728

4.  Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

Authors:  R J Orentas; J E Hildreth; E Obah; M Polydefkis; G E Smith; M L Clements; R F Siliciano
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

5.  Regulation of human immunodeficiency virus env expression by the rev gene product.

Authors:  M L Hammarskjöld; J Heimer; B Hammarskjöld; I Sangwan; L Albert; D Rekosh
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

Review 7.  Cytotoxic T lymphocytes against HIV.

Authors:  B D Walker; F Plata
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

8.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.

Authors:  S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

9.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

10.  Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia.

Authors:  T F Schulz; D Whitby; J G Hoad; T Corrah; H Whittle; R A Weiss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

View more
  7 in total

1.  Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.

Authors:  J M Polo; B A Belli; D A Driver; I Frolov; S Sherrill; M J Hariharan; K Townsend; S Perri; S J Mento; D J Jolly; S M Chang; S Schlesinger; T W Dubensky
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  Virus-specific cytotoxic T-lymphocyte activity elicited by coimmunization with human immunodeficiency virus type 1 genes regulated by the bacteriophage T7 promoter and T7 RNA polymerase protein.

Authors:  M J Selby; B Doe; C M Walker
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Antigen presentation in retroviral vector-mediated gene transfer in vivo.

Authors:  E S Song; V Lee; C D Surh; A Lynn; D Brumm; D J Jolly; J F Warner; S Chada
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 5.  Nucleic acid vaccines.

Authors:  F R Vogel; N Sarver
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

6.  Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens.

Authors:  K Townsend; M Sällberg; J O'Dea; T Banks; D Driver; S Sauter; S M Chang; D J Jolly; S J Mento; D R Milich; W T Lee
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.